A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

10.1136/ijgc-2020-001604

Saved in:

Bibliographic Details
Main Authors:	Ngoi, Natalie YL, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana G, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David SP
Other Authors:	MEDICINE
Format:	Article
Language:	English
Published:	BMJ PUBLISHING GROUP 2020
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Obstetrics & Gynecology ANTITUMOR-ACTIVITY SAFETY
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/177402
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-177402
record_format	dspace
spelling	sg-nus-scholar.10635-1774022024-04-18T02:13:23Z A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA) Ngoi, Natalie YL Heong, Valerie Ow, Samuel Chay, Wen Yee Kim, Hee Seung Choi, Chel Hun Goss, Geraldine Goh, Jeffrey C Tai, Bee Choo Lim, Diana G Kaliaperumal, Nivashini Au, Veonice B Connolly, John E Kim, Jae-Weon Friedlander, Michael Kim, Kidong Tan, David SP MEDICINE MICROBIOLOGY AND IMMUNOLOGY PATHOLOGY SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH Science & Technology Life Sciences & Biomedicine Oncology Obstetrics & Gynecology ANTITUMOR-ACTIVITY SAFETY 10.1136/ijgc-2020-001604 INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 30 8 1239-1242 2020-10-13T07:16:35Z 2020-10-13T07:16:35Z 2020-08-01 2020-10-13T06:56:45Z Article Ngoi, Natalie YL, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana G, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David SP (2020-08-01). A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 30 (8) : 1239-1242. ScholarBank@NUS Repository. https://doi.org/10.1136/ijgc-2020-001604 1048891X 15251438 https://scholarbank.nus.edu.sg/handle/10635/177402 en BMJ PUBLISHING GROUP Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology Obstetrics & Gynecology ANTITUMOR-ACTIVITY SAFETY
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology Obstetrics & Gynecology ANTITUMOR-ACTIVITY SAFETY Ngoi, Natalie YL Heong, Valerie Ow, Samuel Chay, Wen Yee Kim, Hee Seung Choi, Chel Hun Goss, Geraldine Goh, Jeffrey C Tai, Bee Choo Lim, Diana G Kaliaperumal, Nivashini Au, Veonice B Connolly, John E Kim, Jae-Weon Friedlander, Michael Kim, Kidong Tan, David SP A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
description	10.1136/ijgc-2020-001604
author2	MEDICINE
author_facet	MEDICINE Ngoi, Natalie YL Heong, Valerie Ow, Samuel Chay, Wen Yee Kim, Hee Seung Choi, Chel Hun Goss, Geraldine Goh, Jeffrey C Tai, Bee Choo Lim, Diana G Kaliaperumal, Nivashini Au, Veonice B Connolly, John E Kim, Jae-Weon Friedlander, Michael Kim, Kidong Tan, David SP
format	Article
author	Ngoi, Natalie YL Heong, Valerie Ow, Samuel Chay, Wen Yee Kim, Hee Seung Choi, Chel Hun Goss, Geraldine Goh, Jeffrey C Tai, Bee Choo Lim, Diana G Kaliaperumal, Nivashini Au, Veonice B Connolly, John E Kim, Jae-Weon Friedlander, Michael Kim, Kidong Tan, David SP
author_sort	Ngoi, Natalie YL
title	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
title_short	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
title_full	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
title_fullStr	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
title_full_unstemmed	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
title_sort	multicenter phase ii randomized trial of durvalumab (medi-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (mocca)
publisher	BMJ PUBLISHING GROUP
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/177402
_version_	1800914440684568576

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Similar Items